Isbufylline

Research use only, not for human use.

Isbufylline can exert significant anti-inflammatory actions, in addition to its bronchodilator activity.

Isbufylline can exert significant anti-inflammatory actions, in addition to its bronchodilator activity.(In Vivo):At a dose (106 μmol/kg i.p.) providing complete protection against acetylcholine aerosol-induced dyspnea in the guinea pig, Isbufylline inhibited platelet-activating factor (PAF)- and antigen-induced eosinophil infiltration into bronchoalveolar lavage fluid 24 h after the challenge of normal and actively immunized guinea pigs, respectively. In addition, this dose of Isbufylline also inhibited capsaicin-induced extravasation of protein into bronchoalveolar lavage fluid. Isbufylline, 4.2 μmol/kg i.v., significantly inhibited PAF-induced bronchial hyper-responsiveness to i.v. histamine, without exerting evident bronchodilator activity. On the other hand, the bronchodilator, salbutamol, at a dose (10.4 μmol/kg i.p.) was shown to be equieffective to Isbufylline (106 μmol/kg i.p.) for blocking acetylcholine aerosol-induced dyspnea, had no protective action against PAF- or antigen-induced eosinophil recruitment in bronchoalveolar lavage fluid, or against capsaicin-induced plasma protein extravasation. Furthermore, salbutamol (3.5 μmol/kg) significantly potentiated allergen-induced cell infiltration and PAF-induced bronchial hyperresponsiveness.

——

Others

Other Targets

——

——

——

90162-60-0

236.3

C11H16N4O2

>98% (HPLC)

——

CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12

——

(-20℃)

With Ice Pack

≥ 2 years